Amneal Pharmaceuticals Sees 2026 Adj EPS 93c-Adj EPS $1.03 >AMRX
AMRX has more than doubled off its 52-week low of $6.685.
Summary
Amneal Pharmaceuticals has issued its adjusted EPS guidance for the full year 2026, projecting a range of $0.93 to $1.03. This announcement follows closely on the heels of the company's Q4 revenue report and its 2026 revenue guidance, both released just minutes prior. This EPS guidance is a critical component of the company's forward-looking financial outlook, directly impacting analyst models and investor expectations for future profitability. Professional traders will be assessing this guidance against consensus estimates, which could lead to immediate adjustments in stock positioning.
At the time of this announcement, AMRX was trading at $14.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $6.69 to $15.42. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.